(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S.

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take ...

Walt Disney ( DIS) will release its results on Wednesday, with attention on its media networks, theme parks, and streaming services. Analysts expect earnings of $1.47 per share and $23.7bn in revenue, ...

Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine ...

In May, the Danish pharma said CEO Lars Fruergaard Jørgensen would step down, following a turn in the obesity market. While Novo was the star of the emerging weight loss and diabetes market through ...

Danish leader will face a challenging landscape among competitors ...

Delhi: Global healthcare major Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new President and ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...